Injectable testosterone undecanoate for the treatment of hypogonadism
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Injectable testosterone undecanoate (TU) is a long-acting testosterone (T) formulation available for the treatment of male hypogonadism (HG) since 2003. AREAS COVERED: The efficacy and safety of injectable TU are assessed, as obtained by meta-analyzing available evidence. An extensive Medline, Embase and Cochrane search was performed. All uncontrolled and placebo-controlled randomized clinical trials (RCTs), evaluating the effect of injectable TU on different outcomes, were included. Of the 98 retrieved articles, 33 were included in the study. Among those, 11 were placebo-controlled RCTs. Injectable TU was significantly associated with a reduction of fat mass and HbA1c in both controlled and uncontrolled trials, in particular when hypogonadal subjects were enrolled. Similar results were observed for the improvement of erectile function. In addition, TU ameliorated several other outcomes, including blood pressure, lipid profile, waist circumference and body mass index in uncontrolled studies, but these data were not confirmed in placebo-controlled trials. The treatment was well tolerated and no risk of prostate cancer or cardiovascular disease was observed. EXPERT OPINION: Injectable TU is a safe and effective treatment for male HG. The possibility of a therapeutic intervention just four to five times per year frees the patient, at least partially, from having a chronic condition, thus maintaining a positive, active role in self-caring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954 · cited 12×
“A large body of evidence supports a bidirectional association between impaired fasting glucose/insulin resistance, metabolic syndrome (MetS) and low T [65-70].”
BackgroundInfluentialAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Vigen, R. (2013) · JAMA · doi:10.1001/jama.2013.280386 · Cited by 1,003 · cited 2×
“[103] has been submitted to the editor-in-chief of JAMA [110].”
MethodInvestigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Low Serum Testosterone and Mortality in Older Men
Laughlin, G. A., Barrett-Connor, E., & Bergstrom, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1792 · Cited by 798 · cited 1×
“Data from the European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study showed an inverse association between low total T levels and either systolic blood pressure or increased risk of death over the subsequent 20 years, independent of multiple risk factors and several preex…”
BackgroundKhaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., & Day, N. (2007) · Circulation · doi:10.1161/circulationaha.107.719005 · Cited by 743 · cited 1×
“Data from the European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study showed an inverse association between low total T levels and either systolic blood pressure or increased risk of death over the subsequent 20 years, independent of multiple risk factors and several preex…”
BackgroundIncreased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735 · cited 1×
“After publication of the TOM trial, two retrospective analyses have further emphasized the possible CV risk associated with T administration [103,104].”
MethodCalof, O. M., Singh, A. B., Lee, M. L., Kenny, A. M., Urban, R. J., Tenover, J. L., & Bhasin, S. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.11.1451 · Cited by 728 · cited 1×
“Finally, in apparent contrast with three previous meta-analyses [105-107], Xu et al.”
ResultAdverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713 · cited 1×
“Finally, in apparent contrast with three previous meta-analyses [105-107], Xu et al.”
ResultIsidori, A. M., Giannetta, E., Greco, E. A., Gianfrilli, D., Bonifacio, V., Isidori, A., Lenzi, A., & Fabbri, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02339.x · Cited by 695
Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis
Araujo, A. B., Dixon, J. M., Suarez, E. A., Murad, M. H., Guey, L. T., & Wittert, G. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1137 · Cited by 671 · cited 1×
“Three independent meta-analyses demonstrated an association between HG and overall mortality and CV mortality but failed to find any statistical association with incident CV events [96-98].”
BackgroundCaminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444 · cited 6×
“2 Clinical trial report results Of the 99 retrieved articles, 33 were included in the study (Figure 1) [20,27-63].”
BackgroundInfluentialHypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study
Corona, G., Rastrelli, G., Monami, M., Guay, A., Buvat, J., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0447 · Cited by 435 · cited 1×
“Three independent meta-analyses demonstrated an association between HG and overall mortality and CV mortality but failed to find any statistical association with incident CV events [96-98].”
BackgroundSelf-citationCorona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0955 · Cited by 414
Self-citationTestosterone and Metabolic Syndrome: A Meta-Analysis Study
Corona, G., Monami, M., Rastrelli, G., Aversa, A., Tishova, Y., Saad, F., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01991.x · Cited by 400 · cited 12×
“A subanalysis of the BLAST study [62] has recently shown that the reduction in HbA1c levels in men with poorly controlled T2DM depends on the final T concentrations achieved and is more evident in subjects with T levels > 10 nmol/l [65] and in those without depression [86].”
ResultInfluentialSelf-citationType 2 diabetes mellitus and testosterone: a meta-analysis study: Type 2 diabetes and testosterone
Corona, G., Monami, M., Rastrelli, G., Aversa, A., Sforza, A., Lenzi, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2010.01117.x · Cited by 370
Self-citationTrends in androgen prescribing in the United States, 2001 to 2011
Baillargeon, J., Urban, R. J., Ottenbacher, K. J., Pierson, K. S., & Goodwin, J. S. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.6895 · Cited by 336 · cited 1×
“91% in 2011 accounting for $324 million in 2002 to $2 billion in 2011 [5].”
Michalakis, K., Mintziori, G., Kaprara, A., Tarlatzis, B. C., & Goulis, D. G. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.012 · Cited by 321 · cited 1×
“associated factors, besides estrogens, have been suggested as a link among increased fatness and reproductive axis disorders [73,74].”
BackgroundCorona, G., Maseroli, E., Rastrelli, G., Isidori, A. M., Sforza, A., Mannucci, E., & Maggi, M. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.950653 · Cited by 297 · cited 2×
“By meta-analyzing the largest number of studies collected so far, we did not observe any increase in MACE risk associated with T treatment, either when composite or single CV end points were considered [109].”
BackgroundSelf-citationTestosterone supplementation and sexual function: A meta-analysis study
Corona, G., Isidori, A. M., Buvat, J., Aversa, A., Rastrelli, G., Hackett, G., Rochira, V., Sforza, A., Lenzi, A., Mannucci, E., et al. (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12536 · Cited by 263 · cited 3×
“Clinically, an increased ejaculation frequency was registered, indicative of treatment of HG [14,15].”
BackgroundResultSelf-citationOnset of effects of testosterone treatment and time span until maximum effects are achieved
Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0221 · Cited by 232 · cited 2×
“Accordingly, some prospective studies demonstrated that low T level at baseline predicts the development of both T2DM and MetS at follow up [67,83,84,87].”
BackgroundResultHackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., & Wilkinson, P. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12146 · Cited by 182 · cited 7×
“A subanalysis of the BLAST study [62] has recently shown that the reduction in HbA1c levels in men with poorly controlled T2DM depends on the final T concentrations achieved and is more evident in subjects with T levels > 10 nmol/l [65] and in those without depression [86].”
BackgroundInfluentialCorona, G., Rastrelli, G., & Maggi, M. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.05.002 · Cited by 177 · cited 15×
“A subanalysis of the BLAST study [62] has recently shown that the reduction in HbA1c levels in men with poorly controlled T2DM depends on the final T concentrations achieved and is more evident in subjects with T levels > 10 nmol/l [65] and in those without depression [86].”
BackgroundInfluentialSelf-citationHackett, G., Cole, N., Bhartia, M., Kennedy, D., Raju, J., Wilkinson, P., & the BLAST Study Group (2014) · The Journal of Sexual Medicine · doi:10.1111/jsm.12404 · Cited by 168 · cited 5×
“…LOH and MetS 8,4 < 12 40,3 R R R R R Francomano et al. (2014) [60,61] 20 60 58 LOH and MetS 8,3 < 11 30,5 R NR NR NR NR Hackett et al. (2013) [62] Hackett et al. (2014) [86] 97 7,5 61,6 LOH and T2DM 9,2 Mixed 33 R R R NR R Yassin et al. (2014) [63] 261 54 59,5 LOH 7,7 < 12 31,7 R R R NR R Study…”
BackgroundInfluentialFilippi, S., Vignozzi, L., Morelli, A., Chavalmane, A. K., Sarchielli, E., Fibbi, B., Saad, F., Sandner, P., Ruggiano, P., Vannelli, G. B., et al. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01467.x · Cited by 166
Self-citationSvartberg, J., Agledahl, I., Figenschau, Y., Sildnes, T., Waterloo, K., & Jorde, R. (2008) · International Journal of Impotence Research · doi:10.1038/ijir.2008.19 · Cited by 160 · cited 7×
“2 Clinical trial report results Of the 99 retrieved articles, 33 were included in the study (Figure 1) [20,27-63].”
BackgroundInfluentialSaad, F., Aversa, A., M. Isidori, A., & J. Gooren, L. (2012) · Current Diabetes Reviews · doi:10.2174/157339912799424573 · Cited by 148 · cited 6×
“A large body of evidence supports a bidirectional association between impaired fasting glucose/insulin resistance, metabolic syndrome (MetS) and low T [65-70].”
BackgroundResultInfluentialHoyos, C. M., Yee, B. J., Phillips, C. L., Machan, E. A., Grunstein, R. R., & Liu, P. Y. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0525 · Cited by 145 · cited 6×
“2 Clinical trial report results Of the 99 retrieved articles, 33 were included in the study (Figure 1) [20,27-63].”
BackgroundInfluentialGiltay, E. J., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J. G., Saad, F., & Kalinchenko, S. Y. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01859.x · Cited by 140 · cited 6×
“2 Clinical trial report results Of the 99 retrieved articles, 33 were included in the study (Figure 1) [20,27-63].”
BackgroundInfluentialNieschlag, E., Büchter, D., Von Eckardstein, S., Abshagen, K., Simoni, M., & Behre, H. M. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00881.x · Cited by 140
Saad, F., Gooren, L. J., Haider, A., & Yassin, A. (2008) · Journal of Andrology · doi:10.2164/jandrol.107.002774 · Cited by 132
Zitzmann, M., Mattern, A., Hanisch, J., Gooren, L., Jones, H., & Maggi, M. (2013) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02853.x · Cited by 122
Self-citationHow to recognize late-onset hypogonadism in men with sexual dysfunction
Corona, G., Rastrelli, G., Vignozzi, L., Mannucci, E., & Maggi, M. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.138 · Cited by 108 · cited 7×
“, methyltestosterone and fluoxymesterone), which, on one hand, protects them from liver degradation but, on the other hand, increases their hepatotoxicity, and 17a-substituted T preparations are associated with liver cancer, cholestatic jaundice and hemorrhagic cysts [1-3].”
BackgroundInfluentialSelf-citationAversa, A., Bruzziches, R., Francomano, D., Greco, E. A., Fornari, R., Luigi, L. D., Lenzi, A., & Migliaccio, S. (2012) · The Aging Male · doi:10.3109/13685538.2011.631230 · Cited by 108 · cited 6×
“2 Clinical trial report results Of the 99 retrieved articles, 33 were included in the study (Figure 1) [20,27-63].”
BackgroundInfluentialEmerging medication for the treatment of male hypogonadism
Corona, G., Rastrelli, G., Vignozzi, L., & Maggi, M. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.683411 · Cited by 93 · cited 9×
“, methyltestosterone and fluoxymesterone), which, on one hand, protects them from liver degradation but, on the other hand, increases their hepatotoxicity, and 17a-substituted T preparations are associated with liver cancer, cholestatic jaundice and hemorrhagic cysts [1-3].”
BackgroundInfluentialSelf-citationSaad, F., Gooren, L., Haider, A., & Yassin, A. (2007) · Archives of Andrology · doi:10.1080/01485010701730880 · Cited by 87
Corona, G., Rastrelli, G., Balercia, G., Lotti, F., Sforza, A., Monami, M., Forti, G., Mannucci, E., & Maggi, M. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02717.x · Cited by 69
Self-citationHo, C. C. K., Tong, S. F., Low, W. Y., Ng, C. J., Khoo, E. M., Lee, V. K. M., Zainuddin, Z. M., & Tan, H. M. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10755.x · Cited by 53 · cited 2×
“…et al. (2011) [46] 56 13 55,5 LOH and diabetes NR < 10,4 30,7 R NR NR NR R Arafa et al. (2012) [47] 29 25,5 59 LOH with ED 7,2 < 12 NR NR NR R NR R Ho et al. (2012) [48], Tong et al. (2012) [49] 56 12 53,4 LOH 8,9 < 12 NR NR NR NR NR NR Aversa et al. (2012) [50] 40 39 57 LOH and MetS 8,2 < 12 NR…”
BackgroundMoon, D. G., Park, M. G., Lee, S. W., Park, K., Park, J. K., Kim, S. W., Park, N. C., Ahn, T. Y., Paick, J. S., Seo, J. T., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01765.x · Cited by 46 · cited 7×
“2 Clinical trial report results Of the 99 retrieved articles, 33 were included in the study (Figure 1) [20,27-63].”
BackgroundInfluential
Cited by
Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487
Corona, G., Giagulli, V. A., Maseroli, E., Vignozzi, L., Aversa, A., Zitzmann, M., Saad, F., Mannucci, E., & Maggi, M. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0480-2 · Cited by 185
Self-citationObesity and late-onset hypogonadism
Corona, G., Vignozzi, L., Sforza, A., Mannucci, E., & Maggi, M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.031 · Cited by 154
Self-citationGiagulli, V. A., Carbone, M. D., Ramunni, M. I., Licchelli, B., De Pergola, G., Sabbà, C., Guastamacchia, E., & Triggiani, V. (2015) · Andrology · doi:10.1111/andr.12099 · Cited by 109
Treatment of Functional Hypogonadism Besides Pharmacological Substitution
Corona, G., Rastrelli, G., Morelli, A., Sarchielli, E., Cipriani, S., Vignozzi, L., & Maggi, M. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190061 · Cited by 87
Self-citation
Metadata
- Authors
- Corona, G., Maseroli, E., & Maggi, M.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2014-07-31
- Volume
- 15
- Issue
- 13
- Pages
- 1903-1926
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2170432617
- Cited by
- 76
- References
- 39
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.